Launching healthcare products in Germany

Discover key facts about the healthcare market in Germany and learn about our latest market research for our pharmaceutical, medical device, and healthcare sector clients.

Key facts about the German health market:

Funding in the German healthcare system

Germany has a statutory health insurance system, which provides inpatient, outpatient, mental health, and prescription drug coverage. The government has a limited role in the direct delivery of healthcare, with sickness funds (non-governmental insurers) handling administration.

Health technology assessment in the Germany

The federal government has wide-ranging regulatory power over healthcare, but is not directly involved in care delivery.

The Federal Joint Committee (G-BA), which is supervised by the Federal Ministry of Health, determines the medicinal products to be covered by sickness funds.

Coverage decisions are based on evidence from comparative-effectiveness reviews and health technology (benefit-risk) assessments.

Reimbursement of medical devices is dependent on inclusion in new or existing diagnosis-related group (DRG) codes. G-BA/the Institute for Quality and Efficiency in Health Care (IQWiG) will be requested to conduct an assessment before technologies are routinely reimbursed by statutory health insurance (SHI) funds. There are special pathways for digital applications involving the Federal Institute for Drugs and Medical Devices (BfArM).

Germany payers’ primary focus:

The German market is clinically focused first and foremost.

To discuss your German launch strategy with our experts or to enquire about market research services, get in touch using the form below.

    Keep me up to date with the latest news and events.

    Market access in the German-speaking markets

    Market access in the German-speaking markets

    In this webinar, we explore market access challenges in Germany, Austria, and Switzerland. Clare Foy (Director – Global Market Access, Mtech Access) speaks to Dr Stefan Walzer about the challenges and opportunities for reimbursement in the German-speaking markets.

    EU Joint Clinical Assessment (JCA) – implications for Pharma and Medtech cover

    EU Joint Clinical Assessment (JCA) – implications for Pharma and Medtech

    Our health technology assessment experts provide an overview of the EU Joint Clinical Assessment (JCA) and what it means for Pharma and Medical Device manufacturers launching new technologies from 2025

    Market access and reimbursement in key European markets

    Market access and reimbursement in key European markets

    In this introductory guide, our Global market access experts present an overview of the reimbursement landscape in key European healthcare systems, including Germany.